Shares of Fate Therapeutics Inc (NASDAQ:FATE) rose 7.9% during mid-day trading on Tuesday . The stock traded as high as $14.60 and last traded at $14.57. Approximately 638,347 shares changed hands during mid-day trading, a decline of 1% from the average daily volume of 647,898 shares. The stock had previously closed at $13.50.

FATE has been the subject of several research reports. BidaskClub lowered shares of Fate Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 26th. Zacks Investment Research upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. Citigroup started coverage on shares of Fate Therapeutics in a research report on Wednesday, August 1st. They set a “buy” rating and a $20.00 target price for the company. HC Wainwright reiterated a “hold” rating and set a $12.00 target price on shares of Fate Therapeutics in a research report on Tuesday, August 7th. Finally, Wedbush reiterated an “outperform” rating and set a $19.00 target price on shares of Fate Therapeutics in a research report on Tuesday, August 7th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Fate Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.29.

The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $870.20 million, a price-to-earnings ratio of -13.24 and a beta of 1.72.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The business had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative return on equity of 95.07% and a negative net margin of 1,387.53%. The company’s revenue was up .0% compared to the same quarter last year. As a group, equities analysts expect that Fate Therapeutics Inc will post -1.16 earnings per share for the current fiscal year.

In other Fate Therapeutics news, Director Redmile Group, Llc bought 3,703,704 shares of the business’s stock in a transaction on Tuesday, September 25th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $50,000,004.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.89% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in Fate Therapeutics during the second quarter worth about $116,000. PNC Financial Services Group Inc. bought a new position in Fate Therapeutics during the second quarter worth about $120,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Fate Therapeutics in the second quarter worth about $129,000. First Mercantile Trust Co. lifted its holdings in shares of Fate Therapeutics by 113.7% in the second quarter. First Mercantile Trust Co. now owns 12,899 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 6,863 shares in the last quarter. Finally, California Public Employees Retirement System purchased a new stake in shares of Fate Therapeutics in the second quarter worth about $193,000. Hedge funds and other institutional investors own 80.61% of the company’s stock.

About Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Further Reading: What Is An Exchange-Traded Fund (ETF)?

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.